179 related articles for article (PubMed ID: 33637491)
1. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
4. Ventricular tachycardia after initiation of fingolimod.
Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
[TBL] [Abstract][Full Text] [Related]
5. Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.
Ong S; Kibbler J; Maxwell G; Steer J
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171639
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Kum YE; Pamukçu Ö; Canpolat M
Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
[TBL] [Abstract][Full Text] [Related]
7. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
10. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Zięba N; Gębka-Kępińska B; Sowa P
Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
12. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
Zanetta C; Filippi M; Moiola L
Neurol Sci; 2021 May; 42(Suppl 1):9-13. PubMed ID: 33904006
[TBL] [Abstract][Full Text] [Related]
14. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
15. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
16. A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
Gassama S; Garmendia A; Lejeune FX; Boudot de la Motte M; Louapre C; Papeix C; Maillart E; Roux T
Rev Neurol (Paris); 2023 Nov; 179(9):1035-1038. PubMed ID: 37633735
[TBL] [Abstract][Full Text] [Related]
17. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
18. REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.
Batista S; Nunes CC; Cerqueira JJ; Martins Silva A; Correia de Sá J; Ferreira J; Mendonça MT; Pinheiro J; Salgado V; Correia AS; Sequeira J; Costa A; Sousa L
Neurol Sci; 2021 May; 42(5):1995-2003. PubMed ID: 32997282
[TBL] [Abstract][Full Text] [Related]
19. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
Petruzzo M; Lanzillo R
Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
